Clinical Trials Shaping Medical Practice in the Coming Years, Published in Nature Medicine
Gustavo Monnerat, Deputy Editor at The Lancet, shared on LinkedIn:
“Nature Medicine recently published clinical trials most likely to shape medical practice in the coming years.
Among all of them, these are the ones I personally found most interesting:
-> A next-generation tuberculosis vaccine (M72/AS01E)
The current BCG vaccine works reasonably well in young children, but its protection fades in adolescents and adults. This large phase 3 trial, enrolling 20,000 participants across Africa and Asia, aims to prevent progression to active pulmonary TB.
-> Targeting inflammation in heart disease (IL-6 inhibition with ziltivekimab)
This trial moves cardiovascular prevention beyond cholesterol lowering. By targeting residual inflammatory risk, it reinforces a crucial idea of an inflammation cause.
Two approaches stood out:
– mRNA CAR-T therapies that temporarily reprogram immune cells without permanent DNA editing
– Prime editing of autologous stem cells, correcting genetic defects using the patient’s own cells, with early signals suggesting functional cures in rare diseases”
Find more posts on Hemostasis Today.
-
Apr 13, 2026, 09:51Caitlin Raymond: Jehovah’s Witnesses Can Now Accept Their Own Blood But It Is Still Not That Simple
-
Apr 13, 2026, 09:12We Are Pleased to Welcome Rajneesh Jain as the New Chief Executive Officer – Hemophilia Federation (India)
-
Apr 13, 2026, 08:52Deborah Holzapfel: The Reality for Women with Hemophilia B
-
Apr 13, 2026, 08:35Sara Altayeb: ESC 2026 Clinical Pearls for Bleeding on Anticoagulation
-
Apr 13, 2026, 07:58The Case for Greater Investment in VTE Research – JTH
-
Apr 13, 2026, 07:44Mattia Galli: A Clinicial Guide to Navigating Bleeding on Anticoagulant Therapy
-
Apr 13, 2026, 07:31Explore the Power of Guidelines in Hemophilia Care – EAHAD
-
Apr 13, 2026, 06:57Heghine Khachatryan: Why PNH Is More Than a Hemolytic Disease
-
Apr 13, 2026, 05:43Wolfgang Miesbach: A Historic Experiment That Changed Our Understanding of ITP